Compare Enveric Biosciences Inc (ENVB) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Home Depot Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Home Depot Inc trades at $290.44 (market cap $294.79B). The key difference: Home Depot Inc is far larger — about 43351.5× Enveric Biosciences Inc's market cap, and Home Depot Inc pays a 3.15% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Home Depot Inc for 139 Days on average.
| ENVB | HD | |
|---|---|---|
Market Cap | $6.80M | $294.79B |
Volume | 64,867 | 8,693,917 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $391.90 |
52-Week Low | $1.27 | $281.15 |
Typical Hold Time | 14 Days | 139 Days |
Enterprise Value | -$1.49M | $355.27B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Home Depot (HD) trades at $285.77, down 0.32% on the day, with a bearish technical signal despite strong analyst support. The stock shows consistent earnings beats in recent quarters with Q2 2026 EPS of $4.92 exceeding expectations. Revenue reached $159.51B in 2025, though profit margins have declined from 10.87% in 2022 to 9.28% currently. Institutional activity shows mixed positioning with some funds increasing while others reducing holdings.
The stock presents a compelling value opportunity with a consensus price target of $379.93 representing 33% upside potential. However, weakening profit margins, rising mortgage rates impacting housing demand, and bearish technical indicators create near-term headwinds. Long-term prospects remain supported by professional segment growth and housing market tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
